These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 15869736)

  • 1. Treatment of Castleman's disease.
    Dispenzieri A; Gertz MA
    Curr Treat Options Oncol; 2005 May; 6(3):255-66. PubMed ID: 15869736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
    Nishi J; Maruyama I
    Leuk Lymphoma; 2000 Jul; 38(3-4):387-94. PubMed ID: 10830746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Castleman's disease--a two compartment model of HHV8 infection.
    Schulte KM; Talat N
    Nat Rev Clin Oncol; 2010 Sep; 7(9):533-43. PubMed ID: 20603649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.
    Bowne WB; Lewis JJ; Filippa DA; Niesvizky R; Brooks AD; Burt ME; Brennan MF
    Cancer; 1999 Feb; 85(3):706-17. PubMed ID: 10091744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
    Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
    AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman's disease: a single medical center study in Tunisia.
    Chabchoub I; Salah RB; Kallel R; Snoussi M; Frikha F; Marzouk S; Boudawara TS; Bahloul Z
    Rom J Intern Med; 2024 Mar; 62(1):20-32. PubMed ID: 37948573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-associated multicentric Castleman disease.
    Reddy D; Mitsuyasu R
    Curr Opin Oncol; 2011 Sep; 23(5):475-81. PubMed ID: 21760504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Castleman's disease: from basic mechanisms to molecular therapeutics.
    El-Osta HE; Kurzrock R
    Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fifty years of multicentric Castleman's disease.
    Waterston A; Bower M
    Acta Oncol; 2004; 43(8):698-704. PubMed ID: 15764213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of Castleman's Disease.
    Zhang L; Li J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Feb; 38(1):118-21. PubMed ID: 26956866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentric Castleman's disease in India - Does EBV rather than HHV8 play a role?
    Bhanvadia V; Shet T; Rao V; Epari S; Gujral S; Jain H; Bagal B; Sengar M
    Indian J Pathol Microbiol; 2021; 64(2):302-309. PubMed ID: 33851624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathological and therapeutic analysis of Castleman's disease in children].
    Meng QL; Li B; Wang YM; Liu YF; Bao XH; Wang SF; Zhang S
    Zhonghua Er Ke Za Zhi; 2022 Mar; 60(3):227-231. PubMed ID: 35240743
    [No Abstract]   [Full Text] [Related]  

  • 13. Castleman Disease.
    Wang W; Medeiros LJ
    Surg Pathol Clin; 2019 Sep; 12(3):849-863. PubMed ID: 31352991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic multicentric Castleman's disease: a systematic literature review.
    Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
    Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
    Pastor MA; Vasco B; Mosquera JM; Debén G; Bautista P; Requena L
    Actas Dermosifiliogr; 2006; 97(6):385-90. PubMed ID: 16956518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manifestations of three HHV-8-related diseases in an HIV-negative patient: immunoblastic variant multicentric Castleman's disease, primary effusion lymphoma, and Kaposi's sarcoma.
    Codish S; Abu-Shakra M; Ariad S; Zirkin HJ; Yermiyahu T; Dupin N; Boshoff C; Sukenik S
    Am J Hematol; 2000 Dec; 65(4):310-4. PubMed ID: 11074561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Castleman's disease.
    Palestro G; Turrini F; Pagano M; Chiusa L
    Adv Clin Path; 1999; 3(1-2):11-22. PubMed ID: 10655569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Castleman's disease].
    Larroche C; Cacoub P; Godeau P
    Rev Med Interne; 1996; 17(12):1003-13. PubMed ID: 9008748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of Behçet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen.
    Strohal R; Tschachler E; Breyer S; Uthman A; Simonitsch I; Tratting S; Scheithauer W; Stingl G; Kornek GV
    Br J Haematol; 1998 Dec; 103(3):788-90. PubMed ID: 9858232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiofollicular lymph node hyperplasia (Castleman's disease).
    McCarty MJ; Vukelja SJ; Banks PM; Weiss RB
    Cancer Treat Rev; 1995 Jul; 21(4):291-310. PubMed ID: 7585657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.